ClinicalTrials.Veeva

Menu

tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden (MCL-tDCS)

A

Association de Recherche Bibliographique pour les Neurosciences

Status

Enrolling

Conditions

Burden, Caregiver
Lewy Body Dementia With Behavioral Disturbance
Lewy Body Dementia
Dementia With Lewy Bodies
Lewy Body Disease

Treatments

Device: active-tDCS
Device: Sham-tDCS

Study type

Interventional

Funder types

Other

Identifiers

NCT06785948
MCL-tDCS

Details and patient eligibility

About

The goal of this pilot prospective study is to evaluate the effect of tDCS on psychotic-like symptoms in patients with Lewy Body Dementia (LBD). The main questions it aims to answer are:

  • What is the effect of tDCS on neuropsychiatric symptoms, especially psychotic-like symptoms?
  • What is the impact of tDCS on caregiver burden?

Researchers will compare active tDCS (2mA stimulation, anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital) to Sham tDCS (placebo stimulation, no intensity applied) to see if there is an effect on reducing psychotic-like symptoms and on caregiver burden.

Participants will:

  • Undergo a stimulation phase consisting of 10 tDCS sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).
  • perform assessments at T0 (inclusion), T1 (at the end of the stimulation phase), and T2 (follow-up at 8 weeks post stimulation).

Enrollment

30 estimated patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or Female, aged over 60,
  • Diagnosed with a neurodegenerative pathology of the DLB type, at a moderate stage, according to the McKeith and al. (2017) criteria
  • No change in antiparkinsonian or psychotropic medications, or cholinesterase inhibitors, for a period of one month prior to inclusion,
  • Mini Mental State Examination (MMSE) > 15,
  • Composite score called "psychotic factor" (corresponding to the sum of the psychotic-type symptoms sub-scores from the NPI [12]) greater than 0,
  • Presence of a family caregiver,
  • Sufficient written and oral expression in French,
  • Written informed consent signed by the patient and his/her family caregiver

Exclusion criteria

  • History of alcoholism, drug addiction or neurological diseases such as brain trauma, epilepsy, encephalitis, intracranial normal-pressure hydrocephalus, etc. which may lead to cognitive impairment,
  • Concomitant major psychiatric illness,
  • Significant physical illness or comorbidities
  • History of moderate to severe visual impairment secondary to glaucoma, cataract or macular degeneration,
  • Patient under guardianship or curators

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

30 participants in 2 patient groups

Active tDCS
Active Comparator group
Treatment:
Device: active-tDCS
Sham tDCS
Sham Comparator group
Treatment:
Device: Sham-tDCS

Trial contacts and locations

1

Loading...

Central trial contact

Solange HESSE; Kevin POLET, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems